Appeals Court Affirms Gene Therapy Patents
The U.S. Court of Appeals for the Federal Circuit overturned a prior ruling, finding that gene therapy claims are not directed to a natural phenomenon and are therefore patent-eligible under Section 101. The decision restores significant intellectual property protections for innovators. The ruling is expected to positively impact the patent economics for companies like Regenxbio and Sarepta Therapeutics, according to industry analysis.
- The specific patent at the heart of the case is U.S. Patent No. 10,526,617, which covers cultured host cells genetically engineered to contain and produce adeno-associated virus (AAV) variants used in gene therapy. The court found these engineered cells, which are created by chemically splicing nucleic acid sequences from different organisms, are human-made and do not exist in nature. - The lower court's invalidation was based on an analogy to the 1948 Supreme Court case *Funk Brothers*, where a mixture of naturally occurring bacteria was deemed unpatentable. The Federal Circuit found this analogy "flawed," stating that unlike the bacteria in *Funk Brothers*, the recombinant DNA in the engineered host cells results in a cell with a new function and is not nature's handiwork, aligning it more closely with the patent-eligible, human-made bacterium in *Diamond v. Chakrabarty*. - This ruling provides more certainty regarding intellectual property for the foundational tools of viral vector manufacturing, specifically stable producer cell lines. Establishing and patenting these cell lines is a key strategy for overcoming the scalability and consistency challenges inherent in transient transfection methods often used in early-stage development. - The decision is significant for the biomanufacturing industry as it clarifies the application of the Supreme Court's two-part *Alice/Mayo* test for patent eligibility, a framework that has created unpredictability for life sciences companies for over a decade. The Supreme Court has repeatedly declined to hear cases to clarify this area of law, making Federal Circuit rulings particularly impactful. - Securing the patentability of the core production system—the engineered cell itself—strengthens the business case for investing in advanced manufacturing technologies. This includes implementing digital twins for bioprocess optimization, integrated lab automation platforms for process development, and AI/ML models for real-time monitoring and control in GMP environments. - For Contract Development and Manufacturing Organizations (CDMOs), this decision solidifies the value of developing proprietary, high-performance viral vector production platforms. Strong patent protection for these platforms creates a significant competitive advantage and a more stable foundation for partnership and licensing agreements with therapy developers. - The ongoing uncertainty around Section 101 has been cited as a risk factor by investors in the biotechnology sector. By providing a clear win for innovators, this ruling could help de-risk investment in new gene therapy platform technologies, positively impacting the funding climate for both therapeutic companies and the enabling technology/CDMO ecosystem.
